The present study attempts a more definitive analysis of the relationship between fatal colon cancer and use of ERT among women in a large prospective study of adults in the United States.
Women were selected for study from the 676 526 female participants in Cancer Prevention Study II (CPS-II), a prospective mortality study of about 1.2 million American men and women (from all 50 states, the District of Columbia, and Puerto Rico), begun by the American Cancer Society in 1982.
Ever use of ERT was associated with significantly decreased risk of fatal colon cancer (RR=0.71 ; 95% confidence interval [CI]=0.61-0.83).
The reduction in risk was strongest among current users (RR=0.55 ; 95% CI=0.40-0.76), and there was a significant (P=0001) trend of decreasing risk with increasing years of use among all users : Users of 1 year or less had an RR of 0.81 (95% CI=0.63-1.03), while users of 11 years or more had an RR of 0.54 (95% CI=0.39-0.76).
These associations were not altered in multivariate analyses controlling for other risk factors.
In our data, estrogen therapy, particularly recent and long-term use, was associated with a substantial decrease in risk of fatal colon cancer.
These results were consistent with several published studies suggesting a protective role of exogenous estrogens in the development of colorectal cancer and merit further investigation.
Mots-clés Pascal : Tumeur maligne, Côlon, Facteur risque, Oestrogène, Hormone stéroïde sexuelle, Postménopause, Epidémiologie, Etats Unis, Amérique du Nord, Amérique, Prospective, Adulte, Homme, Côlon pathologie, Intestin pathologie, Appareil digestif pathologie
Mots-clés Pascal anglais : Malignant tumor, Colon, Risk factor, Estrogen, Sex steroid hormone, Postmenopause, Epidemiology, United States, North America, America, Prospective, Adult, Human, Colonic disease, Intestinal disease, Digestive diseases
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0352548
Code Inist : 002B13B01. Création : 01/03/1996.